Last update 01 Sep 2025

BioNTech (Shanghai) Pharmaceuticals Co., Ltd.

Subsidiary Company|2021|Shanghai Shi, China

Overview

Tags

Neoplasms
Respiratory Diseases
Skin and Musculoskeletal Diseases
Bispecific antibody
Antibody drug conjugate (ADC)
Biological products

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Neoplasms3
Infectious Diseases1
Top 5 Drug TypeCount
Biological products1
Antibody drug conjugate (ADC)1
Bispecific antibody1
Top 5 TargetCount
HER2 x Top I1
PDL1 x VEGF-A1

Related

3
Drugs associated with BioNTech (Shanghai) Pharmaceuticals Co., Ltd.
Trastuzumab Pamirtecan
Target
HER2 x Top I
Mechanism
HER2 antagonists [+1]
Active Org.
Duality Biologics (Suzhou) Co., Ltd.Duality Biologics (Suzhou) Co., Ltd. [+3]
Originator Org.
Duality Biologics (Suzhou) Co., Ltd.Duality Biologics (Suzhou) Co., Ltd.
Active Indication
HER2-Expressing Endometrial Carcinoma [+12]
Inactive Indication-
Drug Highest PhasePhase 3
First Approval Ctry. / Loc.-
First Approval Date-
Pumitamig
Target
PDL1 x VEGF-A
Mechanism
PDL1 inhibitors [+1]
Active Org.
BioNTech (Shanghai) Pharmaceuticals Co., Ltd. [+2]
Originator Org.
Biotheus, Inc.Biotheus, Inc.
Active Indication
Extensive stage Small Cell Lung Cancer [+27]
Inactive Indication
Advanced Hepatocellular Carcinoma
Drug Highest PhasePhase 3
First Approval Ctry. / Loc.-
First Approval Date-
BNT-3212
Target-
Mechanism-
Active Org.
Zhuhai Pumis Biotechnology Co., Ltd. [+2]
Originator Org.
Zhuhai Pumis Biotechnology Co., Ltd.
Active Indication
Advanced Malignant Solid Neoplasm [+1]
Inactive Indication-
Drug Highest PhasePhase 1/2
First Approval Ctry. / Loc.-
First Approval Date-
2
Clinical Trials associated with BioNTech (Shanghai) Pharmaceuticals Co., Ltd.
CTR20252064
/ Active, not recruitingPhase 2
一项BNT327联合化疗和其他研究药物治疗一线非小细胞肺癌的全球试验的II/III期、多中心、随机主研究方案
[Translation] A Phase II/III, multicenter, randomized, global trial of BNT327 in combination with chemotherapy and other investigational agents in first-line non-small cell lung cancer
CTR20253266
/ Not yet recruitingPhase 1/2
一项在晚期实体瘤成人患者中评价BNT3212单药治疗或与BNT327联合治疗的安全性、耐受性、药代动力学、免疫原性和初步疗效的I/II期、首次人体、开放性、剂量递增和适应症扩展研究
[Translation] A Phase I/II, first-in-human, open-label, dose-escalation and indication expansion study evaluating the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary efficacy of BNT3212 as monotherapy or in combination with BNT327 in adult patients with advanced solid tumors
100 Clinical Results associated with BioNTech (Shanghai) Pharmaceuticals Co., Ltd.
Login to view more data
0 Patents (Medical) associated with BioNTech (Shanghai) Pharmaceuticals Co., Ltd.
Login to view more data
100 Deals associated with BioNTech (Shanghai) Pharmaceuticals Co., Ltd.
Login to view more data
100 Translational Medicine associated with BioNTech (Shanghai) Pharmaceuticals Co., Ltd.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 01 Sep 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
IND Approval
2
3
Phase 2
Login to view more data

Current Projects

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free